Adaptimmune Therapeutics PLC Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Adaptimmune Therapeutics PLC quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q2 2024.
  • Adaptimmune Therapeutics PLC Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $18.2M, a 17.4% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $18.2M -$3.82M -17.4% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $19.4M +$1.49M +8.29% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $20.8M +$2.74M +15.2% Dec 31, 2023 10-Q 2024-08-12
Q3 2023 $21.3M +$3.7M +21% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $22M +$2.65M +13.7% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $17.9M -$3.2M -15.1% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $18M -$2.86M -13.7% Dec 31, 2022 10-K 2024-03-06
Q3 2022 $17.6M -$3.87M -18% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $19.4M +$1.61M +9.05% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $21.1M +$2.82M +15.4% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $20.9M +$2M +10.6% Dec 31, 2021 10-K 2023-03-06
Q3 2021 $21.5M +$2.71M +14.4% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $17.8M -$1.12M -5.93% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $18.3M -$1.17M -6.01% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $18.9M -$1.91M -9.18% Dec 31, 2020 10-K 2022-03-14
Q3 2020 $18.8M -$1.79M -8.7% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $18.9M -$2.62M -12.2% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $19.5M -$4.96M -20.3% Mar 31, 2020 10-Q 2020-05-14
Q4 2019 $20.8M Dec 31, 2019 10-K 2021-02-25
Q3 2019 $20.6M Sep 30, 2019 10-Q 2019-11-06
Q2 2019 $21.5M Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $24.5M Mar 31, 2019 10-Q 2019-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.